Teton Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Teton Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$27K	–	475
2019 Q2	$27K	Hold	10,000	–	–	﹤0.01%	467
2019 Q1	$30K	Hold	10,000	–	–	﹤0.01%	467
2018 Q4	$16K	Hold	10,000	–	–	﹤0.01%	465
2018 Q3	$37K	Hold	10,000	–	–	﹤0.01%	472
2018 Q2	$28K	Hold	10,000	–	–	﹤0.01%	463
2018 Q1	$37K	Buy	+10,000	New	+$32.7K	﹤0.01%	450

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Teton Advisors's ACHN Position: Q3 2019 in Review

Teton Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q3 2019, closing a stake of 10,000 shares — an estimated $27K sold.

Teton Advisors first reported a position in ACHN in Q1 2018 and held it in 6 quarters. The position peaked at $37K in Q3 2018. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

Teton Advisors reported no remaining Achillion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Teton Advisors sold 10,000 Achillion Pharmaceuticals shares in Q3 2019, an estimated $27K.
Teton Advisors first reported a position in Achillion Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Teton Advisors's Achillion Pharmaceuticals position peaked at $37K in Q3 2018.
122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on Teton Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.